Anticonvulsants are becoming increasingly important in the treatment of a variety of pain conditions as a result of these approvals. The anticonvulsant market as a whole is highly genericized; yet, Lyrica, the only branded pharmaceutical among the currently marketed medications, dominates the market for anticonvulsants for Pain Management.

Lyrica (pregabalin), Neurontin (gabapentin), Topamax (topiramate), Depakote (divalproex), and Carbatrol/Tegretol (carbamazepine) are the principal anticonvulsant medications now on the market for the treatment of various types of pain. Lyrica made $5.111 billion pharmaceutical sales in 2012, with 74 percent of that coming from its pain treatment indication. Because all of the other compounds are generic and play a minor role in pain management, the industry will be driven and controlled by sales of the existing blockbuster medicine Lyrica, which accounted for 73.4 percent of total market share in 2011.

The drug's patent exclusivity was slated to expire in 2015, which would have had a detrimental impact on the market by making it entirely generic. Pfizer, on the other hand, has gained market exclusivity for the medicine and its usage in pain management until 2018, so it is expected to keep its dominance.

The demand for anticonvulsant market drugs is being driven by the rising occurrence of epilepsy. Anticonvulsants are used not just for epileptic seizures, but also for migraine and fibromyalgia pain control. This boosts the market for anticonvulsants. The lack of alternate pain management solutions is a significant commercial barrier. Medical devices, such as analgesic pumps, and minimally invasive techniques, such as denervation or rhizotomy, are also used to alleviate pain.

Pain management implants and devices, such as neuromodulators, are gaining traction among medical experts, while acupuncture and acupressure, as well as physiotherapy, are well-known pain reduction techniques. Transcutaneous electrical nerve stimulation (TENS), which administers moderate shocks to nerves to inhibit pain messages to the brain, is another technology used for pain treatment. As a result, competition from other enhanced pain management approaches, gadgets, and pharmaceuticals may stymie the anticonvulsants drug industry. The anticonvulsant market drugs has been categorised by therapeutic class, disease indication, formulation, distribution channel, and other factors.

The research provides an in-depth examination of several customer journeys that are relevant to the market and its sectors. It provides a variety of client perspectives on the products and services. The study digs deeper into their concerns and pain points across a variety of consumer touchpoints. The consultation and business intelligence solutions will assist interested parties, including CXOs, in developing customer experience maps that are tailored to their specific requirements. This will assist them in their efforts to increase customer engagement with their companies.